Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Agenus Inc.
Dozens of specially outfitted RVs will roll out to long-term care facilities in the US to test the prophylactic and symptom-reducing potential of the antibody Lilly is developing with AbCellera.
Research on generic drug coverage in Medicare Part D plans finds access unobstructed for majority of lower cost alternatives. However, study may offer incomplete picture, generic and biosimilar advocates say.
The UK BioIndustry Association has welcomed the government’s fresh investment in COVID-19 vaccine manufacturing capacity, while Sanofi and GSK are striking European and US deals for their vaccine candidate. A number of potential therapies are also being developed, including products based on interferon and hyperimmune globulin, but Roche/Chugai’s Actemra (tocilizumab) looks like a non-runner.
Sixteen applications are in line for US FDA decisions in August. Ten are novel agents.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Antigenics Inc. Aronex Pharmaceuticals AgenTus Therapeutics, Inc. Agenus Royalty Fund, LLC Agenus Switzerland Inc. Agenus UK Limited 4-Antibody